ESR1 and breast carcinoma: By comparing their impact on two subsets of ER + breast cancer cell lines—one with FGFR1 amplification (CAMA1, MDA-MB-134) and the other without (MCF7, T47D)—we confirmed contradictory growth effects and investigated underlying mechanisms.